Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)Some short-term inter-bank bonds performed brilliantly. The yield of 2-year active bonds "21 interest-bearing bonds 02" went down 5bp to reach 1.1%, which was 11bp upside down from the current 1-year active bonds "24 discount bonds 67" yield of 1.21%.
On the 13th, coking coal fell by 2.15%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract coking coal closed at 2501, up or down by -2.15%, with a turnover of 104,800 lots. The position data showed that the top 20 seats were clear, and the difference position was 15,553 lots. The total contract turnover of coking coal futures was 180,200 lots, an increase of 8,845 lots over the previous day. The first 20 seats in the contract held 163,200 lots, an increase of 4,563 lots over the previous day. The short positions in the top 20 seats of the contract were 194,300 lots, an increase of 5,926 lots over the previous day. (Sina Futures)Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.
Jimi Technology: The wholly-owned subsidiary has received the designated notice of development from a well-known domestic automobile main engine factory, and Jimi Technology announced that Yibin Jimi, a wholly-owned subsidiary, has received the designated notice of development from a well-known domestic automobile main engine factory, and will become the designated development supplier of the customer's car projector to supply intelligent cockpit display products.Guoxin Technology: Serialized chip products have been launched in the field of automotive electronic MCU. Guoxin Technology said in an investigation that the company has launched serialized chip products in the field of automotive electronic MCU in recent years, which has been welcomed by the market; Through the implementation of the strategy of "standing on the ground" and "overwhelming", this year, the company's automobile electronic MCU chip business has formed certain advantages, and obvious progress has been made in loading application and shipment volume. The product price is relatively stable, the fluctuation range is small, and the gross profit margin of the product remains relatively stable. In 2024, the company's BMS main control chip CCFC2007PT, high-end domain control chip CCFC3007PT, airbag ignition drive chip CCL1600B, etc. have all been used for loading/installing, and several manufacturers are developing at designated locations based on the above chips. In the future, with the increase of fixed-point mass production projects, shipments are expected to continue to grow.Nigeria: About 130,000 members of Boko Haram have surrendered in the past five months. Christopher Moussa, chief of staff of Nigeria's defense, said on the 12th that nearly 130,000 members of the extremist organization Boko Haram have surrendered in the past five months. Moussa, attending the African Security Watch Conference in Doha, Qatar, said that from July 10th to December 9th, a total of 30,426 Boko Haram militants, 36,774 women and 62,265 children members of the organization surrendered. (Xinhua News Agency)